Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies

被引:35
作者
Utikal, Jochen
Schadendorf, Dirk
Ugurel, Selma [1 ]
机构
[1] German Canc Res Ctr, Skin Canc Unit, D-6900 Heidelberg, Germany
[2] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, D-68135 Mannheim, Germany
关键词
skin cancer; biomarker; prognosis; serum; immunohistochemistry;
D O I
10.1007/s00403-006-0726-5
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Biomarkers are important tools in clinical diagnosis and prognostic classification of various cutaneous malignancies. Besides clinical and histopathological aspects (e.g. anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. We, here, give an overview on currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies, malignant melanoma, squamous cell carcinoma and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
引用
收藏
页码:469 / 477
页数:9
相关论文
共 95 条
[1]   Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma [J].
Acland, K ;
Evans, AV ;
Abraha, H ;
Healy, CMJ ;
Roblin, P ;
Calonje, E ;
Orchard, G ;
Higgins, E ;
Sherwood, R ;
Russell-Jones, R .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (05) :832-835
[2]  
AGRUP P, 1989, ACTA DERM-VENEREOL, V69, P120
[3]   Progression in cutaneous malignant melanoma is associated with distinct expression profiles -: A tissue microarray-based study [J].
Alonso, SR ;
Ortiz, P ;
Pollán, M ;
Pérez-Gómez, B ;
Sánchez, L ;
Acuña, MJ ;
Pajares, R ;
Martínez-Tello, FJ ;
Hortelano, CM ;
Piris, MA ;
Rodríguez-Peralto, JL .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :193-203
[4]   Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma [J].
Andersen, K ;
Nesland, JM ;
Holm, R ;
Florenes, VA ;
Fodstad, O ;
Mælandsmo, GM .
MODERN PATHOLOGY, 2004, 17 (08) :990-997
[5]   Importance of P-cadherin, β-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma [J].
Bachmann, IM ;
Straume, O ;
Puntervoll, HE ;
Kalvenes, MB ;
Akslen, LA .
CLINICAL CANCER RESEARCH, 2005, 11 (24) :8606-8614
[6]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[7]   Automated quantitative analysis of activator protein-2α subcellular expression in melanoma tissue microarrays correlates with survival prediction [J].
Berger, AJ ;
Davis, DW ;
Tellez, C ;
Prieto, VG ;
Gershenwald, JE ;
Johnson, MM ;
Rimm, DL ;
Bar-Eli, M .
CANCER RESEARCH, 2005, 65 (23) :11185-11192
[8]  
BLESCH A, 1994, CANCER RES, V54, P5695
[9]  
BOGDAHN U, 1989, CANCER RES, V49, P5358
[10]  
Bosserhoff AK, 1997, CANCER RES, V57, P3149